Spyre Therapeutics (SYRE) has released an update to notify the public and investors about its officers.
Alison Lawton stepped down from the Board on February 1, 2024, with Mark McKenna stepping in to fill the vacancy the same day. McKenna brings a wealth of experience, having held senior roles at prestigious firms like Prometheus Biosciences and Bausch Health Companies, and is currently involved with McKenna Capital Partners. As part of his board appointment, McKenna will be compensated with cash and stock options, aligning with the company’s existing compensation program. Additionally, the company has amended its CEO’s employment agreement to increase severance benefits under certain conditions.
For further insights into SYRE corporate activity, check out TipRanks’ Insiders Trading Activity page.
For a comprehensive understanding of the announcement, you can read the full document here.
